These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 19435898)

  • 1. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
    Mukherjee B; McEllin B; Camacho CV; Tomimatsu N; Sirasanagandala S; Nannepaga S; Hatanpaa KJ; Mickey B; Madden C; Maher E; Boothman DA; Furnari F; Cavenee WK; Bachoo RM; Burma S
    Cancer Res; 2009 May; 69(10):4252-9. PubMed ID: 19435898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
    Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
    Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.
    Golding SE; Morgan RN; Adams BR; Hawkins AJ; Povirk LF; Valerie K
    Cancer Biol Ther; 2009 Apr; 8(8):730-8. PubMed ID: 19252415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-PKcs deficiency inhibits glioblastoma cell-derived angiogenesis after ionizing radiation.
    Liu Y; Zhang L; Liu Y; Sun C; Zhang H; Miao G; Di CX; Zhou X; Zhou R; Wang Z
    J Cell Physiol; 2015 May; 230(5):1094-103. PubMed ID: 25294801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
    Struve N; Binder ZA; Stead LF; Brend T; Bagley SJ; Faulkner C; Ott L; Müller-Goebel J; Weik AS; Hoffer K; Krug L; Rieckmann T; Bußmann L; Henze M; Morrissette JJD; Kurian KM; Schüller U; Petersen C; Rothkamm K; O Rourke DM; Short SC; Kriegs M
    Oncogene; 2020 Apr; 39(15):3041-3055. PubMed ID: 32066879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
    McEllin B; Camacho CV; Mukherjee B; Hahm B; Tomimatsu N; Bachoo RM; Burma S
    Cancer Res; 2010 Jul; 70(13):5457-64. PubMed ID: 20530668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sp1 Upregulation Bolsters the Radioresistance of Glioblastoma Cells by Promoting Double Strand Breaks Repair.
    Liu X; Sun C; Wang Q; Li P; Zhao T; Li Q
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma.
    Reichert S; Rödel C; Mirsch J; Harter PN; Tomicic MT; Mittelbronn M; Kaina B; Rödel F
    Radiother Oncol; 2011 Oct; 101(1):51-8. PubMed ID: 21852011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear GSK3β induces DNA double-strand break repair by phosphorylating 53BP1 in glioblastoma.
    Yang Y; Lei T; Du S; Tong R; Wang H; Yang J; Huang J; Sun M; Wang Y; Dong Z
    Int J Oncol; 2018 Mar; 52(3):709-720. PubMed ID: 29328365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
    Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
    J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
    Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
    Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin.
    Li B; Yuan M; Kim IA; Chang CM; Bernhard EJ; Shu HK
    Oncogene; 2004 Jun; 23(26):4594-602. PubMed ID: 15077177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.